MIM
PDSB icon

MetLife Investment Management’s PDS Biotechnology PDSB Stock Holding History

MetLife Investment Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,026
Closed -$59.5K – 2913
2024
Q1 		$59.5K Buy
15,026
+98
+0.7% +$505 ﹤0.01% 2691
2023
Q4 		$74.2K Hold
14,928
– – ﹤0.01% 2725
2023
Q3 		$75.4K Hold
14,928
– – ﹤0.01% 2729
2023
Q2 		$75.1K Buy
+14,928
New +$97.8K ﹤0.01% 2825
2018
Q2 		– Sell
-505
Closed -$12K – 2208
2018
Q1 		$12K Buy
+505
New +$136K ﹤0.01% 2181

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's PDSB Position: Q2 2024 in Review

MetLife Investment Management sold out of PDS Biotechnology (PDSB) in Q2 2024, closing a stake of 15,026 shares — an estimated $59.5K sold.

MetLife Investment Management first reported a position in PDSB in Q1 2018 and held it in 5 quarters. The position peaked at $75.4K in Q3 2023. 77 funds tracked by Wall St. Rank hold PDSB as of Q2 2024.

  • MetLife Investment Management reported no remaining PDS Biotechnology position as of Q2 2024 after selling out during the quarter.
  • MetLife Investment Management sold 15,026 PDS Biotechnology shares in Q2 2024, an estimated $59.5K.
  • MetLife Investment Management first reported a position in PDS Biotechnology in Q1 2018 and held it in 5 quarters.
  • MetLife Investment Management's PDS Biotechnology position peaked at $75.4K in Q3 2023.
  • 77 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2024.

Based on MetLife Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.